You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Baxter
McKinsey
Colorcon
Johnson and Johnson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,226,907

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,226,907
Title:Cardiac muscle function and manipulation
Abstract: A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure in a mammal.
Inventor(s): Zhou; Mingdong (La Jolla, CA)
Assignee: Zensun (Shanghai) Science & Technology Limited (Shanghai, CN)
Application Number:09/980,672
Patent Claims:1. A method of inducing remodeling of cardiac muscle cell sarcomeric and cytoskeleton structures or cell-cell adhesions, which method comprises contacting cardiac muscle cells with a neuregulin protein consisting of the amino acid sequence set forth in SEQ ID NO:2, in the amount sufficient to activate the MAP kinase pathway in said cardiac muscle cells and induce remodeling of said cardiac muscle cell sarcomeric and cytoskeleton structures or cell-cell adhesions.

2. The method of claim 1, wherein the neuregulin protein is used in an amount that is at least 10.sup.-8M.

3. The method of claim 1, wherein the cardiomyocyte or the cardiac muscle cells exist in a mammal.

4. The method of claim 3, wherein the mammal is a human.

5. The method of claim 4, wherein the human has or is suspected of having a heart failure.

6. The method of claim 5, wherein the heart failure is a disease state selected from the group consisting of congestive heart failure, myocardial infarction, tachyarrhythmia, familial hypertrophic cardiomyopathy, ischaemic heart disease, idiopathic dilated cardiomyopathy and myocarditis.

7. The method of claim 5, wherein the heart failure is in the form of ischaemic, congenital, rheumatic, or idiopathic.

8. The method of claim 5, wherein the heart failure results from disassociation of cardiac muscle cell-cell adhesion and/or the disarray of sarcomeric structures in the mammal.

9. The method of claim 3, wherein the neuregulin protein is administered with a pharmaceutically acceptable carrier or excipient.

10. The method of claim 1, wherein the contact of the cardiac muscle cells with the neuregulin protein decreases DNA synthesis in the cardiac muscle cells.

11. The method of claim 1, wherein the contact of the cardiac muscle cells with the neuregulin protein results in sustained activation of the MAP kinase pathway in the cardiac muscle cells.

12. The method of claim 3, wherein the neuregulin protein is administered orally, using a sustained-release system or via injection or infusion.

13. The method of claim 12, wherein the injection or infusion is selected from the group consisting of intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial and intralesional injection or infusion.

14. The method of claim 1, which further comprises contacting the cardiac muscle cells with an effective amount of an agent which causes cardiac hypertrophy or congestive heart failure.

15. The method of claim 14, wherein the agent which causes cardiac hypertrophy or congestive heart failure is fludrocortisone acetate or herceptin.

16. The method of claim 1, which further comprises contacting the cardiac muscle cells with an effective amount of an agent that acts to suppress a hypertrophy induction pathway different from the pathway suppressed by the neuregulin.

17. The method of claim 16, wherein the agent that acts to suppress a hypertrophy induction pathway different from the pathway suppressed by the neuregulin is selected from the group consisting of a cardiotrophic inhibitor, an angiotensin-converting enzyme (ACE) inhibitor, a human growth hormone, an IGF-I, an anti-hypertrophic, myocardiotrophic factor, an anti-arrhythmic factor and an inotropic factor.

18. The method of claim 1, which further comprises contacting the cardiac muscle cells with an effective amount of an angiotensin-converting enzyme (ACE) inhibitor.

19. The method of claim 18, wherein the ACE inhibitor is selected from the group consisting of quinapril, ramipril, captopril, benazepril, fosinopril, lisinopril, enalapril and lisinopril.

20. The method of claim 1, which further comprises contacting the cardiac muscle cells with an effective amount of an agent for treating hypertension.

21. The method of claim 20, wherein the agent for treating hypertension is selected from the group consisting of an antibody to the endothelin receptor, a .beta.-adrenoreceptor antagonist, an .alpha..sub.1-noreceptor antagonist, an anti-oxidant, a .beta.-blocker and a growth hormone.

22. A method for treating or delaying disassociation of cardiac muscle cell-cell adhesion and/or the disarray of sarcomeric structures in a mammal, which method comprises administering to a mammal, to which such treatment or delay is needed or desirable, a neuregulin protein consisting of the amino acid sequence set forth in SEQ ID NO:2, in an amount sufficient to activate the MAP kinase pathway in said mammal, whereby said disassociation of cardiac muscle cell-cell adhesion and/or the disarray of sarcomeric structures is treated or delayed in said mammal.

23. The method of claim 22, wherein the mammal is a human.

24. The method of claim 23, wherein the human has or is suspected of having a heart failure.

25. The method of claim 24, wherein the heart failure is a disease state selected from the group consisting of congestive heart failure, myocardial infarction, tachyarrhythmia, familial hypertrophic cardiomyopathy, ischaemic heart disease, idiopathic dilated cardiomyopathy and myocarditis.

26. The method of claim 24, wherein the heart failure is in the form of ischaemic, congenital, rheumatic, or idiopathic.

27. The method of claim 22, wherein administration of the neuregulin protein decreases DNA synthesis in the cardiac muscle cells of the mammal.

28. The method of claim 22, wherein administration of the neuregulin protein results in sustained activation of the MAP kinase pathway in the cardiac muscle cells of the mammal.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPP7850Dec 21, 1998
PCT Information
PCT FiledDecember 21, 1999PCT Application Number:PCT/AU99/01137
PCT Publication Date:June 29, 2000PCT Publication Number:WO00/37095

Details for Patent 7,226,907

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Zensun (Shanghai) Science & Technology Limited (Shanghai, CN) 2018-12-21 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Express Scripts
Mallinckrodt
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.